Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons

References

• Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010, 11, 1230–1239.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ 3rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med 2009, 10, 586–593.
   PubMed Web of Science ®Google Scholar
• Bennett GJ. Neuropathic pain: new insights, new interventions. Hosp Pract (Minneap) 1998, 33, 95–8, 101.
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009, 122, S22–S32.
   PubMed Web of Science ®Google Scholar
• Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009, 9, 71–78.
   PubMedGoogle Scholar
• Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001, 21, 1375–1388.
   PubMed Web of Science ®Google Scholar
• Nash EM, Sangha KS. Levetiracetam. Am J Health Syst Pharm 2001, 58, 1195–1199.
   Google Scholar
• Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 2003, 473, 27–33.
   PubMed Web of Science ®Google Scholar
• Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 2006, 10, 193–198.
   PubMed Web of Science ®Google Scholar
• Ozcan M, Ayar A, Canpolat S, Kutlu S. Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy. Acta Anaesthesiol Scand 2008, 52, 926–930.
   PubMed Web of Science ®Google Scholar
• Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001, 42 Suppl 4, 13–18.
   PubMed Web of Science ®Google Scholar
• McCarter GC, Reichling DB, Levine JD. Mechanical transduction by rat dorsal root ganglion neurons in vitro. Neurosci Lett 1999, 273, 179–182.
   Google Scholar
• Klusáková I, Dubový P. Experimental models of peripheral neuropathic pain based on traumatic nerve injuries – an anatomical perspective. Ann Anat 2009, 191, 248–259.
   PubMed Web of Science ®Google Scholar
• Vyklický L, Knotková-Urbancovä H. Can sensory neurones in culture serve as a model of nociception? Physiol Res 1996, 45, 1–9.
   PubMed Web of Science ®Google Scholar
• Vanegas H, Schaible H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000, 85, 9–18.
   PubMed Web of Science ®Google Scholar
• Ozcan M, Ayar A, Alcin E, Ozcan S, Kutlu S. Effects of levobupivacaine and bupivacaine on intracellular calcium signaling in cultured rat dorsal root ganglion neurons. J Recept Signal Transduct Res 2010, 30, 115–120.
   PubMed Web of Science ®Google Scholar
• Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 2005, 19, 35–43.
   PubMedGoogle Scholar
• Klitgaard H, Pitkänen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003, 5 Suppl 1, S9–16.
   Google Scholar
• Archer DP, Lamberty Y, Wang B, Davis MJ, Samanani N, Roth SH. Levetiracetam reduces anesthetic-induced hyperalgesia in rats. Anesth Analg 2007, 104, 180–185.
   PubMed Web of Science ®Google Scholar
• Sliva J, Dolezal T, Prochazkova M, Votava M, Krsiak M. Preemptive levetiracetam decreases postoperative pain in rats. Neuro Endocrinol Lett 2008, 29, 953–957.
   Google Scholar
• Rossi S, Mataluni G, Codecà C, Fiore S, Buttari F, Musella A, Castelli M, Bernardi G, Centonze D. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009, 16, 360–366.
   PubMed Web of Science ®Google Scholar
• Jorns TP, Johnston A, Zakrzewska JM. Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. Eur J Neurol 2009, 16, 740–744.
   PubMed Web of Science ®Google Scholar
• Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. Eur J Pain 2011, 15, 608–614.
   PubMed Web of Science ®Google Scholar
• Del Pozo E, Pereira-Pérez E, González-Contreras LG. [The effectiveness of levetiracetam in the treatment of neuropathic pain]. Rev Neurol 2011, 53, 65–72.
   Google Scholar
• Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001, 10, 279–286.
   PubMed Web of Science ®Google Scholar
• Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F, Bernardi G, Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45, 719–728.
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4, 18–61.
   PubMed Web of Science ®Google Scholar
• Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 2007, 48, 1842–1849.
   PubMed Web of Science ®Google Scholar
• Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001, 306, 5–8.
   PubMed Web of Science ®Google Scholar
• Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003, 45, 661–671.
   PubMed Web of Science ®Google Scholar
• Lee CH, Lee CY, Tsai TS, Liou HH. PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochem Pharmacol 2008, 76, 225–235.
   Google Scholar
• Nadeau H, McKinney S, Anderson DJ, Lester HA. ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. J Neurophysiol 2000, 84, 1062–1075.
   PubMed Web of Science ®Google Scholar
• Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett 2008, 436, 289–293.
   PubMedGoogle Scholar
• Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 2005, 313, 720–730.
   PubMed Web of Science ®Google Scholar
• Costa C, Martella G, Picconi B, Prosperetti C, Pisani A, Di Filippo M, Pisani F, Bernardi G, Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006, 37, 1319–1326.
   PubMed Web of Science ®Google Scholar
• Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43, 9–18.
   PubMed Web of Science ®Google Scholar